233 related articles for article (PubMed ID: 23043073)
1. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.
Cantore A; Nair N; Della Valle P; Di Matteo M; Màtrai J; Sanvito F; Brombin C; Di Serio C; D'Angelo A; Chuah M; Naldini L; Vandendriessche T
Blood; 2012 Nov; 120(23):4517-20. PubMed ID: 23043073
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
[TBL] [Abstract][Full Text] [Related]
6. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy.
Nair N; Rincon MY; Evens H; Sarcar S; Dastidar S; Samara-Kuko E; Ghandeharian O; Man Viecelli H; Thöny B; De Bleser P; VandenDriessche T; Chuah MK
Blood; 2014 May; 123(20):3195-9. PubMed ID: 24637359
[TBL] [Abstract][Full Text] [Related]
7. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice.
Suwanmanee T; Hu G; Gui T; Bartholomae CC; Kutschera I; von Kalle C; Schmidt M; Monahan PE; Kafri T
Mol Ther; 2014 Mar; 22(3):567-574. PubMed ID: 23941813
[TBL] [Abstract][Full Text] [Related]
8. What´s new in Gene Therapy of Hemophilia.
Rodriguez-Merchan EC
Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
[TBL] [Abstract][Full Text] [Related]
9. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
10. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
Zhang R; Wang Q; Zhang L; Chen S
Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
[TBL] [Abstract][Full Text] [Related]
11. Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy.
Di Matteo M; Samara-Kuko E; Ward NJ; Waddington SN; McVey JH; Chuah MK; VandenDriessche T
Mol Ther; 2014 Sep; 22(9):1614-24. PubMed ID: 25034357
[TBL] [Abstract][Full Text] [Related]
12. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
13. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
[TBL] [Abstract][Full Text] [Related]
14. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
[TBL] [Abstract][Full Text] [Related]
16. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
[TBL] [Abstract][Full Text] [Related]
17. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
[TBL] [Abstract][Full Text] [Related]
18. Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells.
Dodd M; Marquez-Curtis L; Janowska-Wieczorek A; Hortelano G
J Gene Med; 2014; 16(5-6):131-42. PubMed ID: 24947827
[TBL] [Abstract][Full Text] [Related]
19. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
[TBL] [Abstract][Full Text] [Related]
20. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice.
Annoni A; Cantore A; Della Valle P; Goudy K; Akbarpour M; Russo F; Bartolaccini S; D'Angelo A; Roncarolo MG; Naldini L
EMBO Mol Med; 2013 Nov; 5(11):1684-97. PubMed ID: 24106222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
